FDA's Transparency Initiative Enters The "What Is The Right Thing To Do" Phase: An Interview With Principal Deputy Commissioner Sharfstein
• By The Pink Sheet
In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments from the public; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to "The Pink Sheet" about its initial findings
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.
Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.
The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.